Excellent
Fully Aligned
Patient Risk:
Low
Summary
The provided content describes metformin-associated lactic acidosis risk, recognition features, and label-based management (immediate discontinuation and prompt hemodialysis), and it correctly ties key precautions to label sections (renal impairment, contrast, drug interactions, hepatic impairment, age-related renal monitoring). No unsupported or contradictory claims are present relative to the supplied label excerpts.
Category Scores
Accurate Statements
There have been postmarketing cases of metformin-associated lactic acidosis, including fatal cases, with subtle onset and nonspecific symptoms.
Warnings and Precautions (5.1) Lactic Acidosis
If metformin-associated lactic acidosis is suspected, institute general supportive measures promptly in a hospital setting and discontinue JANUMET immediately.
Warnings and Precautions (5.1) Lactic Acidosis
Prompt hemodialysis is recommended to correct the acidosis and remove accumulated metformin; metformin is dialyzable and hemodialysis has often resulted in reversal of symptoms and recovery.
Warnings and Precautions (5.1) Lactic Acidosis
Educate patients and families about symptoms of lactic acidosis and instruct them to discontinue JANUMET and report symptoms.
Warnings and Precautions (5.1) Lactic Acidosis
Renal impairment is a primary risk factor; assess eGFR before initiation and periodically thereafter; JANUMET is contraindicated with eGFR <30 mL/min/1.73 m2 and not recommended for eGFR 30 to <45 due to dose availability.
Warnings and Precautions (5.1) Lactic Acidosis; Recommendations for Use in Renal Impairment (2.2)
Age 65 or greater increases risk; assess renal function more frequently in elderly patients.
Warnings and Precautions (5.1) Lactic Acidosis (Age 65 or Greater)
For iodinated contrast imaging procedures, stop JANUMET at the time of or prior to the procedure for specified eGFR/liver disease/alcoholism/heart failure/intra-arterial contrast scenarios; re-evaluate eGFR 48 hours after and restart if stable.
Warnings and Precautions (5.1) Lactic Acidosis; Discontinuation for Iodinated Contrast Imaging Procedures (2.3)
Concomitant use with drugs that impair renal function, cause significant hemodynamic change, interfere with acid-base balance, or increase metformin accumulation may increase lactic acidosis risk; consider more frequent monitoring.
Warnings and Precautions (5.1) Lactic Acidosis (Drug Interactions discussion)
Carbonic anhydrase inhibitors may increase risk of lactic acidosis; examples include topiramate, zonisamide, acetazolamide, dichlorphenamide.
Drug Interactions (7) Carbonic Anhydrase Inhibitors
Drugs that reduce metformin clearance (e.g., OCT2/MATE inhibitors) may increase systemic exposure to metformin and lactic acidosis risk.
Drug Interactions (7) Drugs that Reduce Metformin Clearance
Warn patients against excessive alcohol intake while receiving JANUMET.
Warnings and Precautions (5.1) Lactic Acidosis (Excessive Alcohol Intake); Drug Interactions (7) Alcohol
Patients with acute or chronic metabolic acidosis (including diabetic ketoacidosis) are contraindicated; severe renal impairment (eGFR <30 mL/min/1.73 m2) is contraindicated.
Contraindications (4)
JANUMET is not recommended in patients with hepatic impairment.
8.7 Hepatic Impairment; Warnings and Precautions (5.1) Lactic Acidosis (Hepatic Impairment)
The adverse reactions section notes that lactic acidosis is also discussed elsewhere in labeling.
Adverse Reactions (6) (relevant cross-reference): Lactic Acidosis discussed in Warnings and Precautions (5.1)
Unsupported Statements
Contradictions
Important Omissions
Whether the labeling includes a boxed warning for lactic acidosis is not directly supported by the provided excerpts (the evaluation scope is limited to the supplied label text).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
Claims match the supplied label excerpts regarding recognition and risk-mitigation steps (discontinue immediately and consider hemodialysis, plus risk-factor-linked precautions such as eGFR/contrast/alcohol/interacting drugs and hepatic impairment). No mismatches were found within the provided text.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Fully Aligned
Primary Issue
Suggested Improvement
If the goal is to explicitly address whether it is a boxed warning, include the label excerpt that states the boxed-warning status; the provided text does not clearly confirm boxing.